During the last three months, 7 analysts shared their evaluations of Intellia Therapeutics (NASDAQ:NTLA), revealing diverse outlooks from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 4 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 1 | 0 | 0 | 0 |
| 2M Ago | 0 | 1 | 0 | 0 | 0 |
| 3M Ago | 2 | 2 | 0 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Intellia Therapeutics, presenting an average target of $70.86, a high estimate of $120.00, and a low estimate of $54.00. A 5.34% drop is evident in the current average compared to the previous average price target of $74.86.
Exploring Analyst Ratings...
Login or create a forever free account to read this news
Sign up/Log in